5 recruiting, 4 not yet recruiting. 9 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Recruiting 5, Not yet recruiting 4 |
| Phase 1 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Multiple Myeloma Refractory: new trials by email Literature Review of Multiple Myeloma Refractory trials Research Report on Multiple Myeloma Refractory
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma BAFF CAR-T - Non-Hodgkin Lymphoma Refractory/ Relapsed, Multiple Myeloma Refractory | Phase 2 | Not yet recruiting | Luminary Therapeutics | 90 | 2026-12-01 | 2026-08-18 |
| Elranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Dexamethasone, Mezigdomide, Elranatamab - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | PETHEMA Foundation | 60 | 2026-11-01 | 2026-10-28 |
| A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma Elranatamab, Tocilizumab - Multiple Myeloma (MM), Multiple Myeloma Refractory | Phase 2 | Recruiting | SCRI Development Innovations, LLC | 46 | 2026-09-01 | 2026-09-04 |
| CAR-T in Relapsed/Refractory Multiple Myeloma CAR-T - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Recruiting | Dr. Zaineb Akram | 10 | 2026-06-01 | 2026-07-08 |
| Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. Autologous BCMA-targeting CAR T cells - Multiple Myeloma in Relapse, Multiple Myeloma Refractory | Phase 1 / Phase 2 | Not yet recruiting | Hebei Senlang Biotechnology Inc., Ltd. | 24 | 2026-02-01 | 2026-02-19 |
| Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Inobrodib, Pomalidomide, Dexamethasone - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 2 | Recruiting | CellCentric Ltd. | 100 | 2026-01-22 | 2026-09-21 |
| Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma Teclistamab - Multiple Myleoma, Multiple Myeloma in Relapse | Phase 2 | Not yet recruiting | Gruppo Italiano Malattie EMatologiche dell'Adulto | 52 | 2025-11-01 | 2025-04-03 |
| Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients HuL001, Lenalidomide/Dexamethasone - Multiple Myeloma Refractory | Phase 1 / Phase 2 | Recruiting | HuniLife Biotechnology, Inc. | 21 | 2025-08-18 | 2026-09-18 |
| Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma anti BCMA CAR-T cells - Multiple Myeloma Refractory | Phase 1 / Phase 2 | Recruiting | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 30 | 2025-02-01 | 2026-10-16 |
Multiple Myeloma (8) · Recurrence (4) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm, Residual (1) · Neoplasms (1)
Blood Protein Disorders (8) · Cardiovascular Diseases (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Hemorrhagic Disorders (8) · Hemostatic Disorders (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphoproliferative Disorders (8) · Neoplasms by Histologic Type (8) · Neoplasms, Plasma Cell (8) · Paraproteinemias (8) · Vascular Diseases (8) · Neoplasms (7) · Pathologic Processes (5)
Dexamethasone (3) · CCS1477 (1) · Lenalidomide (1) · pomalidomide (1) · tocilizumab (1)
CellCentric Ltd. (1) · Dr. Zaineb Akram (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Hebei Senlang Biotechnology Inc., Ltd. (1) · HuniLife Biotechnology, Inc. (1) · Luminary Therapeutics (1) · Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology (1) · PETHEMA Foundation (1) · SCRI Development Innovations, LLC (1)
United States (2) · Belarus (1) · Pakistan (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Albert Oriol, PhD (1) · Enrique Ocio, PhD (1) · Francesco Zaja (1) · Hans Lee, MD (1) · Jin Lu (1) · Maisie Huang, PhD (1) · Maryam Khan, MBBS, MRCP (UK), FCPS(Cl Haem) (1) · Mikhail Uss, MD (1) · Naseer Qayum (1) · Tariq Ghafoor (1)